Document:

Online Disruptive Technologies, Inc.: Exhibit 10.1 - Filed by newsfilecorp.com

THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE
“SUBSCRIPTION AGREEMENT”) RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE
TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO
REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE
“1933 ACT”).

NONE OF THE SECURITIES TO WHICH THIS SUBSCRIPTION AGREEMENT
RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT OR ANY U.S. STATE SECURITIES
LAWS AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD, DIRECTLY OR
INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED HEREIN) EXCEPT
IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN
AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE
SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933 ACT. 

PRIVATE PLACEMENT SUBSCRIPTION 

ONLINE DISRUPTIVE TECHNOLOGIES, INC.

INSTRUCTIONS TO SUBSCRIBER: 

	1. 	
      COMPLETE the information on Page 2 of this
      Subscription Agreement. You must reside outside North America to use
      this form.

	 	 
	2. 	
      DELIVER the Subscription Proceeds, in the form of
      bank draft or wire transfer (wire transfer instructions will be provided
      upon request), together with one originally executed copy of this entire
      Subscription Agreement to Online Disruptive Technologies, Inc. (the
      “Company”), at

3120 S. Durango Drive, Suite 305

Las Vegas, Nevada 89117 

or to such other address as is
provided by Eyal Davidovits, a director of the Company.

	3. 	
      EMAIL a copy of Page 2 of this Subscription
      Agreement to Giora Davidovits, CEO, GioraD@Savicell.com, to Robbie Manis,
      consultant, robbiem@savicell.com, and to Clark Wilson LLP, counsel for
      Online Disruptive Technologies, Inc., attention Bernard Pinsky
      (bip@cwilson.com).

Clark Wilson LLP are authorized to release any funds
received from Subscribers to Online Disruptive Technologies, Inc. immediately
upon receipt.

ONLINE DISRUPTIVE TECHNOLOGIES, INC. 

PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT 

The undersigned (the “Subscriber”) hereby irrevocably
subscribes for and agrees to purchase from Online Disruptive Technologies, Inc.
(the “Company”) that number of common stocks of the Company, par value
$0.001 (the “Shares”) set out below at a price of $0.20 per Share. The
Subscriber agrees to be bound by the terms and conditions set forth in the
attached Subscription Agreement terms and conditions.

	Subscriber Information 	 	Shares to be Purchased 
	 	 	 
	 	 	Number of Shares:
      5,000,000                                              
       x $$0.20 
	 	 	 
	(Name of Subscriber) 	 	 
	 	 	 
	 	 	= 
	Account Reference (if applicable):
    ____________________________	 	 
	 	 	 
	 	 	Aggregate Subscription
      Price:$1,000,000.                                          
	X 	 	(the “Subscription Proceeds”) 
	(Signature of Subscriber – if the Subscriber is an Individual)
    	 	 
	 	 	 
	 	 	 
	X 	 	 
	(Signature of Authorized Signatory – if the Subscriber is not
      an Individual) 	 	Please complete if purchasing as agent or
      trustee for a principal (beneficial 
	 	 	purchaser) (a “Disclosed Principal”) and not
      purchasing as trustee or agent for 
	 	 	accounts fully managed by it. 
	(Name and Title of Authorized Signatory – if the Subscriber is
      not an 	 	 
	Individual) 	 	 
	 	 	(Name of Disclosed Principal) 
	 	 	 
	(SIN, SSN, or other Tax Identification Number of the
      Subscriber) 	 	 
	 	 	(Address of Disclosed Principal) 
	 	 	 
	(Subscriber’s Address, including city and province or state or
      residence) 	 	 
	 	 	(Account Reference, if applicable) 
	 	 	 
	 	 	 
	 	 	(SIN, SSN, or other Tax Identification Number of
      Disclosed Principal) 
	(Telephone
      Number)                                                 (Email
      Address) 	 	 
	 	 	 
	Register the Shares as set forth below:
	 	Deliver the Shares as set forth
      below: 
	 	 	 
	 	 	 
	(Name to Appear on Share Certificate) 	 	(Attention - Name) 
	 	 	 
	 	 	 
	(Account Reference, if applicable) 	 	(Account Reference, if applicable) 
	 	 	 
	 	 	 
	 	 	(Address, including Postal Code) 
	(Address, including Postal Code) 	 	 
	 	 	 
	 	 	(Telephone Number) 

ACCEPTANCE 

The Company hereby accepts the subscription as set forth above
on the terms and conditions contained in this Subscription Agreement, as of the
30th day of June, 2015. 

ONLINE DISRUPTIVE TECHNOLOGIES, INC. 

 

Per: 
_______________________________
                      
Authorized Signatory 

- 2 - 

THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE
“SUBSCRIPTION AGREEMENT”) RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE
TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO
REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE
“1933 ACT”).

NONE OF THE SECURITIES TO WHICH THIS SUBSCRIPTION AGREEMENT
RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT OR ANY U.S. STATE SECURITIES
LAWS AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD, DIRECTLY OR
INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED HEREIN) EXCEPT
IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN
AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE
SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933 ACT. 

PRIVATE PLACEMENT SUBSCRIPTION 
(Offshore Subscribers
Only Outside North America) 

	TO: 	ONLINE DISRUPTIVE TECHNOLOGIES,
      INC. (the “Company”) 
	  	3120 S. Durango Drive, Suite 305
    
	  	Las Vegas, Nevada, 89117
  

Purchase of Shares 

	1. 	
      SUBSCRIPTION

	 	 
	1.1 	
      The undersigned (the “Subscriber”) hereby
      irrevocably subscribes for and agrees to purchase common shares (the
      “Shares”) in the amount set out on Page 2 of this Subscription
      Agreement, at a price of US $0.20 per Share (such subscription and
      agreement to purchase being the “Subscription”), for the total
      subscription price as set out on Page 2 of this Subscription Agreement
      (the “Subscription Proceeds”), which Subscription Proceeds are
      tendered herewith, on the basis of the representations and warranties and
      subject to the terms and conditions set forth herein.

	 	 
	1.2 	
      The Company hereby agrees to sell the Shares to the
      Subscriber on the basis of the representations and warranties and subject
      to the terms and conditions set forth herein. Subject to the terms hereof,
      the Subscription Agreement will be effective upon its acceptance by the
      Company. The Subscriber acknowledges that the offering of Shares
      contemplated hereby is not subject to any minimum aggregate subscription
      level.

	 	 
	1.3 	
      Unless otherwise provided, all dollar amounts referred to
      in this Subscription Agreement are in lawful money of the United States of
      America.

	 	 
	2. 	
      PAYMENT

	 	 
	2.1 	
      Subject to the fulfilment of the Company’s obligations
      hereunder, the Subscription Proceeds shall be wired directly to the
      Company in accordance with wire instructions that will be provided by the
      Company on request. Alternatively the Subscription Proceeds may be wired
      to Clark Wilson LLP, attorneys for the Company, and Clark Wilson LLP are
      authorized and instructed to immediately deliver the Subscription Proceeds
      to the Company.

- 3 - 

- 4 - 

	2.2 	
      The Company may treat the Subscription Proceeds as a
      non-interest bearing loan and may use the Subscription Proceeds prior to
      this Subscription Agreement being accepted by the Company and the
      certificates representing the Securities have been issued to the
      Subscriber.

	 	 
	2.3 	
      The Subscriber must complete, sign and return to the
      Company an executed copy of this Subscription Agreement.

	 	 
	2.4 	
      The Subscriber shall complete, sign and return to the
      Company as soon as possible, on request by the Company, any documents,
      questionnaires, notices and undertakings as may be required by regulatory
      authorities, stock exchanges and/or applicable law.

	 	 
	3. 	
      CLOSING

	 	 
	3.1 	
      Closing of the purchase and sale of the Shares shall
      occur on or before May 15, 2015, or on such other date or dates as may be
      mutually agreed by the Company and the Subscriber (the “Closing
      Date”), but there is no minimum number of Shares being offered. The
      Subscriber acknowledges that Shares may be issued to other subscribers
      under this offering (the “Offering”).

	 	 
	4. 	
      FURTHER PARTICIPATION IN EQUITY FINANCINGS/ BOARD
      SEAT

	 	 
	4.1 	
      The Subscriber shall have the following rights of
      participation, provided that all representations of the Subscriber in this
      Subscription Agreement remain true as at the date of exercise of the said
      rights:

	 	 
	4.2 	
      The Subscriber will have the right, exercisable until
      November 30, 2016, to subscribe for up to $500,000 in Shares on the same
      price as contained in this Subscription Agreement (the “Further
      Placement Right”). The Further Placement Right will be subject to
      adjustment in case of any share consolidation or share split (“Share
      Adjustment”) in the same proportion as such Share
Adjustment.

	 	 
	4.3 	
      The Subscriber will have the non-transferrable right to
      subscribe for up to three point five (3.5%) percent of any private
      placement of Shares or units comprising Shares and warrants invested by an
      arm’s length third party (the “Third Party Placement”) on the same
      terms as the Third Party Placement (the “Participation Right”)
      exercisable until May 30, 2019. The Participation Right will not apply to
      (a) the Company in its discretion issuing Shares by making a strategic
      acquisition or receiving an investment from a business partner or joint
      venture participant where there is a business relationship outside of the
      investment (“Strategic Shares”) and (b) any existing rights to
      acquire Shares which have been publicly disclosed or stock options to be
      granted (“Existing Share Rights”). Where Strategic Shares are
      issued, the Minimum Equity Requirement for the Board Seat Right (both
      terms defined in section 4.4) will have the Strategic Shares excluded from
      the calculation.

	 	 
	4.4 	
      The Subscriber will have the right, for so long as it is
      the registered or beneficial owner of three point five (3.5%) percent of
      the outstanding Common Shares of the Company (the “Minimum Equity
      Requirement”), to nominate one director pre-approved by the Company to
      the board of the subsidiary of the Company, Savicell Diagnostics Ltd., an
      Israeli company (the “Board Seat Right”). For the purpose of
      calculating the outstanding Shares of the Company, any Strategic Shares
      issued after the closing of this subscription will be excluded.

	 	 
	5. 	
      ACKNOWLEDGEMENTS OF SUBSCRIBER

	 	 
	5.1 	
      The Subscriber acknowledges and agrees
  that:

- 5 - 

	 	(a) 	
      the Securities have not been registered under the U.S.
      Securities Act of 1933, as amended (the “1933 Act”), or under any
      securities or “blue sky” laws of any state of the United States and are
      being offered only in a transaction not involving any public offering
      within the meaning of the 1933 Act, and, unless so registered, may not be
      offered or sold in the United States or to a U.S. Person, as that term is
      defined in Regulation “S” (“Regulation “S”) promulgated by the
      Securities and Exchange Commission (the “SEC”) pursuant to the 1933
      Act, except in accordance with the provisions of Regulation “S”, pursuant
      to an effective registration statement under the 1933 Act, or pursuant to
      an exemption from, or in a transaction not subject to, the registration
      requirements of the 1933 Act, and in each case only in accordance with
      applicable state securities laws;

	 	 	 
	 	(b) 	
      the Company will refuse to register any transfer of any
      of the Shares not made in accordance with the provisions of Regulation S,
      pursuant to an effective registration statement under the 1933 Act or
      pursuant to an available exemption from, or in a transaction not subject
      to, the registration requirements of the 1933 Act;

	 	 	 
	 	(c) 	
      the decision to execute this Subscription Agreement and
      purchase the Shares has not been based upon any oral or written
      representation as to fact or otherwise made by or on behalf of the Company
      and such decision is based solely upon information provided by the Company
      in this Subscription Agreement and information filed by the Company on
      EDGAR (the “Company Information”).

	 	 	 
	 	(d) 	
      the Subscriber and the Subscriber's advisor(s) have had a
      reasonable opportunity to review the Company Information and to ask
      questions of and receive answers from the Company regarding the Offering,
      and to obtain additional information, to the extent possessed or
      obtainable without unreasonable effort or expense, necessary to verify the
      accuracy of the information contained in the Company Information, or any
      other document provided to the Subscriber;

	 	 	 
	 	(e) 	
      by execution hereof the Subscriber has waived the need
      for the Company to communicate its acceptance of the purchase of the
      Shares pursuant to this Subscription Agreement;

	 	 	 
	 	(f) 	
      the Company is entitled to rely on the representations
      and warranties and the statements and answers of the Subscriber contained
      in this Subscription Agreement and the Subscriber will hold harmless the
      Company from any loss or damage it may suffer as a result of the
      Subscriber's failure to correctly complete this Subscription
    Agreement;

	 	 	 
	 	(g) 	
      the Subscriber and the Company will indemnify and hold
      harmless the other party and, where applicable, its respective directors,
      officers, employees, agents, advisors and shareholders from and against
      any and all loss, liability, claim, damage and expense whatsoever
      (including, but not limited to, any and all fees, costs and expenses
      whatsoever reasonably incurred in investigating, preparing or defending
      against any claim, lawsuit, administrative proceeding or investigation
      whether commenced or threatened) arising out of or based upon any
      acknowledgment, representation or warranty of the Subscriber or the
      Company and Savicell contained herein or in any other document furnished
      by the Subscriber, the Company or Savicell in connection herewith, being
      untrue in any material respect or any breach or failure by the Subscriber
      or the Company to comply with any covenant or agreement made by the
      Subscriber or the Company in connection therewith;

	 	 	 
	 	(h) 	
      the issuance and sale of the Shares to the Subscriber
      will not be completed if it would be unlawful or if, in the discretion of
      the Company acting reasonably, it is not in the best interests of the
      Company;

- 6 - 

	 	(i) 	
      the Subscriber has been advised to consult the
      Subscriber’s own legal, tax and other advisors with respect to the merits
      and risks of an investment in the Shares and with respect to the
      applicable resale restrictions, and it is solely responsible (and the
      Company is not in any way responsible) for compliance with:

	 	 	 	 
	 		(i) 	
      any applicable laws of the jurisdiction in which the
      Subscriber is resident in connection with the distribution of the Shares
      hereunder, and

	 	 	 	 
	 		(ii) 	
      applicable resale
restrictions.

	 	(j) 	
      the Subscriber has not acquired the Shares as a result
      of, and will not itself engage in, any “directed selling efforts” (as
      defined in Regulation S) in the United States in respect of any of the
      Shares which would include any activities undertaken for the purpose of,
      or that could reasonably be expected to have the effect of, conditioning
      the market in the United States for the resale of any of the Shares;
      provided, however, that the Subscriber may sell or otherwise dispose of
      any of the Shares pursuant to registration of any of the Shares pursuant
      to the 1933 Act and any applicable state securities laws or under an
      exemption from such registration requirements and as otherwise provided
      herein;

	 	 	 
	 	(k) 	
      the Subscriber is not a U.S. Person (as defined in
      Regulation S), is outside the United States when receiving and executing
      this Subscription Agreement and is acquiring the Shares as principal for
      its own account or for account of the Disclosed Principal, as applicable,
      for investment purposes only, and not with a view to, or for, resale,
      distribution or fractionalization thereof, in whole or in part, and no
      other person has a direct or indirect beneficial interest in such Shares,
      other than the Disclosed Principal, if applicable;

	 	 	 
	 	(l) 	
      the statutory and regulatory basis for the exemption
      claimed for the offer and sale of the Shares, although in technical
      compliance with Regulation S, would not be available if the offering is
      part of a plan or scheme to evade the registration provisions of the 1933
      Act;

	 	 	 
	 	(m) 	
      the Company has advised the Subscriber that the Company
      is relying on an exemption from the requirements to provide the Subscriber
      with a prospectus and to sell the Shares through a person registered to
      sell securities and, as a consequence of acquiring the Shares pursuant to
      this exemption, certain protections, rights and remedies, including
      statutory rights of rescission or damages, will not be available to the
      Subscriber;

	 	 	 
	 	(n) 	
      the Shares are listed on the OTC Bulletin Board but no
      trading market exists, and no representation has been made to the
      Subscriber that a trading market for the Shares will develop;

	 	 	 
	 	(o) 	
      the Subscriber acknowledges that the Company has not
      undertaken, and will have no obligation, to register any of the Shares
      under the 1933 Act;

	 	 	 
	 	(p) 	
      neither the SEC, nor any other securities regulatory
      authority has reviewed or passed on the merits of the Shares;

	 	 	 
	 	(q) 	
      no documents in connection with this Offering have been
      reviewed by the SEC, nor by any other securities regulatory authority or
      state securities administrators;

	 	 	 
	 	(r) 	
      there is no government or other insurance covering any of
      the Shares; and

	 	 	 
	 	(s) 	
      this Subscription Agreement is not enforceable by the
      Subscriber unless it has been accepted by the Company, and the Subscriber
      acknowledges and agrees that the Company reserves the right to reject any
      subscription for any reason.

- 7 - 

	6. 	
      REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE
      SUBSCRIBER

	 	 
	6.1 	
      The Subscriber hereby represents and warrants to and
      covenants with the Company, as of the date of this Agreement and as of the
      Closing Date (which representations, warranties and covenants shall
      survive the Closing Date) that:

	 	(a) 	
      the Subscriber is outside the United States when
      receiving and executing this Subscription Agreement;

	 	 	 
	 	(b) 	
      the Subscriber is not a “U.S. Person”, as defined in
      Regulation S;

	 	 	 
	 	(c) 	
      the Subscriber is not acquiring the Shares for the
      account or benefit of, directly or indirectly, any U.S. Person, as defined
      in Regulation S;

	 	 	 
	 	(d) 	
      the Subscriber is resident in the jurisdiction set out on
      Page 2 of this Subscription Agreement;

	 	 	 
	 	(e) 	
      the Subscriber:

	 	(i) 	
      is knowledgeable of, or has been independently advised as
      to, the applicable securities laws of the securities regulators having
      application in the jurisdiction in which the Subscriber is resident (the
      “International Jurisdiction”) which would apply to the acquisition
      of the Shares,

	 	 	 
	 	(ii) 	
      is purchasing the Shares pursuant to exemptions from
      prospectus or equivalent requirements under applicable securities laws or,
      if such is not applicable, the Subscriber is permitted to purchase the
      Shares under the applicable securities laws of the securities regulators
      in the International Jurisdiction without the need to rely on any
      exemptions,

	 	 	 
	 	(iii) 	
      acknowledges that the applicable securities laws of the
      authorities in the International Jurisdiction do not require the Company
      to make any filings or seek any approvals of any kind whatsoever from any
      securities regulator of any kind whatsoever in the International
      Jurisdiction in connection with the issue and sale or resale of the
      Shares, and

	 	 	 
	 	(iv) 	
      represents and warrants that the acquisition of the
      Shares by the Subscriber does not trigger:

	 	A. 	
      any obligation to prepare and file a prospectus or
      similar document, or any other report with respect to such purchase in the
      International Jurisdiction, or

	 	 	 
	 	B. 	
      any continuous disclosure reporting obligation of the
      Company in the International Jurisdiction, and

	 	 	 
	 	C. 	
      the Subscriber will, if requested by the Company, deliver
      to the Company a certificate or opinion of local counsel from the
      International Jurisdiction which will confirm the matters referred to in
      subparagraphs (ii), (iii) and (iv) above to the satisfaction of the
      Company, acting reasonably;

	 	(f) 	
      the Subscriber is acquiring the Shares as principal, or
      for account of the Disclosed Principal, as applicable, and for investment
      only and not with a view to, or for, resale, distribution or
      fractionalization thereof, in whole or in part, and, in particular, it, or
      the Disclosed Principal, has no intention to distribute either directly or
      indirectly any of the Securities in the United States or to U.S. Persons
      (as defined in Regulation S);

- 8 - 

	 	(g) 	
      the Subscriber acknowledges that it has not acquired the
      Shares as a result of, and will not itself engage in, any “directed
      selling efforts” (as defined in Regulation S) in the United States in
      respect of any of the Shares which would include any activities undertaken
      for the purpose of, or that could reasonably be expected to have the
      effect of, conditioning the market in the United States for the resale of
      any of the Shares; provided, however, that the Subscriber may sell or
      otherwise dispose of any of the Shares pursuant to registration of any of
      the Securities pursuant to the 1933 Act and any applicable state
      securities laws or under an exemption from such registration requirements
      and as otherwise provided herein;

	 	 	 
	 	(h) 	
      the Subscriber has the legal capacity and competence to
      enter into and execute this Subscription Agreement and to take all actions
      required pursuant hereto and, if the Subscriber is a corporation, it is
      duly incorporated and validly subsisting under the laws of its
      jurisdiction of incorporation and all necessary approvals by its
      directors, shareholders and others have been obtained to authorize
      execution and performance of this Subscription Agreement on behalf of the
      Subscriber;

	 	 	 
	 	(i) 	
      the entering into of this Subscription Agreement and the
      transactions contemplated hereby do not result in the violation of any of
      the terms and provisions of any law applicable to, or, if applicable, the
      incorporation documents of, the Subscriber, or of any agreement, written
      or oral, to which the Subscriber may be a party or by which the Subscriber
      is or may be bound;

	 	 	 
	 	(j) 	
      the Subscriber has duly executed and delivered this
      Subscription Agreement and it constitutes a valid and binding agreement of
      the Subscriber enforceable against the Subscriber;

	 	 	 
	 	(k) 	
      the Subscriber has received and carefully read this
      Subscription Agreement;

	 	 	 
	 	(l) 	
      the Subscriber (i) has adequate net worth and means of
      providing for its current financial needs and possible personal
      contingencies, (ii) has no need for liquidity in this investment, and
      (iii) is able to bear the economic risks of an investment in the Shares
      for an indefinite period of time, and can afford the complete loss of such
      investment;

	 	 	 
	 	(m) 	
      the Subscriber is able to fend for itself in the
      subscription, has the degree of knowledge, education and experience in
      financial and business matters as to enable the Subscriber to evaluate the
      merits and risks of the investment in the Shares and the
Company;

	 	 	 
	 	(n) 	
      the Subscriber understands and agrees that the Company
      and others will rely upon the truth and accuracy of the acknowledgements,
      representations, warranties, covenants and agreements contained in this
      Subscription Agreement, and agrees that if any of such acknowledgements,
      representations and agreements are no longer accurate or have been
      breached, the Subscriber shall promptly notify the Company;

	 	 	 
	 	(o) 	
      the Subscriber is aware that an investment in the Company
      is speculative and involves certain risks, including the possible loss of
      the investment;

	 	 	 
	 	(p) 	
      the Subscriber is not an underwriter of, or dealer in,
      the Company's Securities, nor is the Subscriber participating, pursuant to
      a contractual agreement or otherwise, in the distribution of the
      Shares;

	 	 	 
	 	(q) 	
      the Subscriber has made an independent examination and
      investigation of an investment in the Shares and the Company and has
      depended on the advice of its legal and financial advisors and agrees that
      the Company will not be responsible in anyway whatsoever for the
      Subscriber's decision to invest in the Shares and the
  Company;

- 9 - 

	 	(r) 	
      if the Subscriber is acquiring the Shares as a fiduciary
      or agent for one or more investor accounts, the Subscriber has sole
      investment discretion with respect to each such account, and the
      Subscriber has full power to make the foregoing acknowledgements,
      representations and agreements on behalf of such account;

	 	 	 
	 	(s) 	
      the Subscriber is not aware of any advertisement in the
      United States of any of the Securities and is not acquiring the Shares as
      a result of any form of general solicitation or general advertising in the
      United States including advertisements, articles, notices or other
      communications published in any newspaper, magazine or similar media or
      broadcast over radio or television, or any seminar or meeting whose
      attendees have been invited by general solicitation or general
      advertising; and

	 	 	 
	 	(t) 	
      no person has made to the Subscriber any written or oral
      representations:

	 	(i) 	
      that any person will resell or repurchase any of the
      Securities,

	 	 	 
	 	(ii) 	
      that any person will refund the purchase price of any of
      the Securities,

	 	 	 
	 	(iii) 	
      as to the future price or value of any of the Securities,
      or

	 	 	 
	 	(iv) 	
      that any of the Securities will be listed and posted for
      trading on any stock exchange or that application has been made to list
      and post any of the Securities of the Company on any stock
  exchange.

	6.2 	
      In this Subscription Agreement, the term “U.S. Person”
      shall have the meaning ascribed thereto in Regulation S promulgated under
      the 1933 Act and for the purpose of the Subscription Agreement includes
      any person in the United States.

	 	 
	7. 	
      REPRESENTATIONS AND WARRANTIES BY COMPANY AND
      SAVICELL

	 	 
	7.1 	
      The Company, on its behalf and on behalf of its only
      subsidiary, Savicell Diagnostic Ltd., an Israeli company
      (“Savicell”), hereby represents and warrants to and covenants with
      the Subscriber, as of the date of this Subscription Agreement and as of
      the Closing Date (which representations, warranties and covenants shall
      survive the Closing Date) that:

	 	(a) 	
      Incorporation; Authority. Each of Company and
      Savicell is duly incorporated and validly existing under the laws of the
      State of Nevada and the State of Israel, respectively, and has corporate
      power to own or lease its property and to carry on its business as now
      conducted and as proposed to be conducted pursuant to the Budget (as
      defined below). Each of Company and Savicell has obtained all necessary
      corporate and other authorizations and approvals to carry out its
      obligations hereunder. This Subscription Agreement when executed and
      delivered by or on behalf of the Company, shall be duly and validly
      authorized, executed and delivered by the Company and shall constitute the
      valid and legally binding obligations of the Company, legally enforceable
      against the Company in accordance with its respective terms.

	 	 	 
	 		
      Each of the Company and Savicell is solvent, has not
      committed an act of bankruptcy, has not proposed a compromise/arrangement
      with its creditors generally and has not taken any proceedings in this
      respect, has not taken any proceedings to have itself declared bankrupt,
      has not taken any proceedings to have a receiver appointed over its
      assets, has not had any execution enforceable upon any of its assets, and
      has not taken any action for voluntary winding-up. There has not been, and
      there are currently no, petition/proceedings for a receiving/liquidation/
      bankruptcy order filed against Company.

- 10 - 

	 	(b) 	
      Share Capital.

	 	 	 	 
	 		(i) 	
      Share Capital of Savicell. The registered share
      capital of Savicell immediately following the Closing shall be NIS
      100,000, divided into 10,000,000 Shares, of which 11,627 Shares were
      issued and outstanding as of March 1, 2015, 1,765 Shares are reserved for
      issuance to Ramot at Tel Aviv University Ltd. under the Ramot License
      Agreement (as defined below). Except for the transactions contemplated by
      this Subscription Agreement, and except as set forth in this Section
      7.1(b), and shares issued and subscriptions received from other
      subscribers of Savicell private placements since March 1, 2015, there are
      no other share capital, outstanding warrants, options or other rights to
      subscribe for, purchase or acquire from the Savicell any share capital or
      other securities of the Savicell and there are not any contracts or
      binding commitments providing for the issuance of, or the granting of
      rights to acquire, any share capital or other securities of the Savicell
      or under which the Savicell is, or may become, obligated to issue any of
      its securities. All issued and outstanding share capital of the Savicell
      has been duly authorized, and is validly issued and outstanding and fully
      paid and non-assessable. If requested in writing, the Company will provide
      to the Subscriber an update as to the number of shares outstanding in
      Savicell as at March 31, 2015, and such update will form a part of this
      Agreement as a representation of the Company.

	 	 	 	 
	 		(ii) 	
      Share Capital of the Company. The authorized share
      capital of the Company on March 19, 2015 was 500,000,000 shares of Common
      Stock with a par value of $0.001 of which 82,636,433 shares of Common
      Stock were issued and outstanding and 20,000,000 shares of Preferred Stock
      with a par value of $0.001 of which none were issued and outstanding.
      Except for the transactions contemplated by this Subscription Agreement,
      and except as set forth in this Section 7, and except management debt
      conversion agreements, a form of which were filed on EDGAR during April
      2015, and except subscriptions for shares and further investment rights
      closed in April and May 2015 and disclosed on EDGAR, and except options
      authorized but not yet granted, and except granted options disclosed
      below, there are no other share capital, outstanding warrants, options or
      other rights to subscribe for, purchase or acquire from the Company any
      share capital or other securities of the Company and there are not any
      contracts or binding commitments providing for the issuance of, or the
      granting of rights to acquire, any share capital or other securities of
      the Company or under which the Company is, or may become, obligated to
      issue any of its securities. All issued and outstanding share capital of
      the Company has been duly authorized, and is validly issued and
      outstanding and fully paid and non-assessable.

	 	 	 	 
	 		(iii) 	
      The Shares, when issued and allotted in accordance with
      this Subscription Agreement, will be duly authorized, validly issued,
      fully paid, nonassessable, will have the rights, preferences, privileges,
      and restrictions set forth in the Articles, and will be free and clear of
      any liens, claims, encumbrances or third party rights of any kind
      (collectively: “Encumbrances”) and duly registered in the name of
      the Investor in the Company's register of shareholders. Since its
      incorporation, there has been no declaration or payment by the Company of
      dividends, or any distribution by the Company of any assets of any kind to
      any of its shareholders in redemption of or as the purchase price for any
      of the Company's securities.

	 	 	 	 
	 		(iv) 	
      The Company granted options to purchase 14,237,075 shares
      of Common Stock. Each grant of options was duly authorized by all
      necessary corporate action and the award agreement governing such grant
      (if any) was duly executed and delivered by each party thereto, each such
      grant was made in all material respects in accordance with the terms of
      the applicable compensation plan or arrangement of the Company under which
      it was granted and all other applicable legal requirements. The Company
      has never adjusted or amended the exercise price of any options previously
      awarded, whether through amendment, cancellation, replacement grant,
      repricing or any other mean.

- 11 - 

	 	(c) 	
      Directors and Officers. The Company’s officers and
      director are Giora Davidovits and Eyal Davidovits and Benjamin Cherniak.
      Savicell officers and directors are Giora Davidovits, Rami Hadar, Eyal
      Davidovits and Irit Arbel.

	 	 	 
	 	(d) 	
      Financial Position. The Company and Savicell have
      no material liabilities or obligations to third parties, other than
      disclosed in their financial statements filed on EDGAR. Company’s and
      Savicell’s assets, if any, are free and clear of any
Encumbrance.

	 	 	 
	 	(e) 	
      Agreements; Intellectual Property. Savicell and
      Ramot at Tel Aviv University Ltd. are parties to an exclusive, worldwide
      license, in the field of monitoring and/or analyzing of metabolic activity
      profiles, under Prof. Fernando Patolsky technology (including patent
      application) relating to early detection of diseases by measuring
      metabolic activity in the immune system (“Ramot License
      Agreement”). Savicell has obtained in this Ramot License Agreement the
      right to use all intellectual property sufficient for use in the conduct
      of its business as currently conducted and as proposed to be conducted
      pursuant to the Budget to the extent such conduct relies on Ramot
      agreement. Other than the Ramot License Agreement, Savicell is not a party
      to any material agreement except relating to operations or financings
      conducted in the ordinary course of business. The Company is not a party
      to any material agreement except relating to operations or
    financings.

	 	 	 
	 	(f) 	
      No Default. Neither the execution and delivery of
      this Subscription Agreement nor compliance by the Company with the terms
      and provisions hereof or thereof, will conflict with, or result in a
      breach or violation by Company of, any of the terms, conditions and
      provisions of: (i) the Articles, (ii) any agreement, contract, lease,
      license or commitment to which Company is a party or to which it is
      subject, or (iii) applicable law or any judgment, ruling or other biding
      decision of any authorized body/authority. To the best of its knowledge,
      Company or Savicell is not in default or breach of any material contracts,
      agreements, written or oral, indentures or other instruments to which it
      is a party.

	 	 	 
	 	(g) 	
      Records. The minute books of the Company and
      Savicell contain materially accurate and complete copies of the minutes of
      meetings of the Company's shareholders and the boards of directors (and
      any committee thereof). The corporate records of the Company have been
      maintained in accordance with all applicable statutory requirements and
      are complete and accurate in all material respects.

	 	 	 
	 	(h) 	
      Interested Party Transactions. Other than
      potential conversion of debt owing to management to shares, and other than
      employment packages, there are no existing arrangements between the
      Company or Savicell and any Company's or Savicell’s officer/office holder,
      director, or holder of more than 5% of the share capital of the Company,
      or any affiliate or associate of any such person. No employee,
      shareholder, officer, or director of the Company is indebted to the
      Company or to Savicell. There are inter-corporate agreements and loans
      among Savicell and the Company.

	 	 	 
	 	(i) 	
      Budget. The budget of Savicell has been prepared
      in good faith and with reasonable care.

	 	 	 
	 	(j) 	
      Use of Proceeds. Company and Savicell intends to
      use the proceeds from the investment contemplated hereunder for general
      working capital purposes and for other purposes pursuant to a budget for
      activities in the field of disease monitoring and medical devices which
      shall be approved by the Company’s or Savicell’s Board of Directors from
      time to time.

	 	 	 
	 	(k) 	
      Litigation. There is no litigation, proceeding or
      governmental investigation in progress, pending, or to the Company's or
      Savicell’s knowledge, threatened or contemplated against or relating to
      the Company or Savicell and/or their employees/office holders/securities
      holders (in their capacity as such). To Company’s and Savicell’s best
      knowledge, there are no causes or grounds to initiate any such claims,
      proceedings or investigations.

- 12 - 

	 	(l) 	
      Full Disclosure. Neither this Subscription
      Agreement nor any certificates made or delivered by the Company or
      Savicell in connection herewith contains any untrue statement of a
      material fact or omits to state a material fact necessary to make the
      statements herein or therein not misleading, in view of the circumstances
      in which they were made. To the best knowledge of the Company or Savicell,
      there are, and have been, no events or transactions, or facts or
      information, which have not been disclosed to Subscriber in writing and
      which have or could reasonably be expected to have a material adverse
      effect on the Company or Savicell.

	8. 	
      ACKNOWLEDGEMENT AND WAIVER

	 	 
	8.1 	
      The Subscriber has acknowledged that the decision to
      purchase the Shares was made based solely on the Company Information and
      the representations in this Agreement. Because the Subscriber is not
      purchasing the Shares under a prospectus, the Subscriber will not have the
      civil protections, rights and remedies that would otherwise be available
      to the Subscriber under the securities laws in the United States,
      including statutory rights of rescission or damages.

	 	 
	9. 	
      REPRESENTATIONS AND WARRANTIES WILL BE RELIED UPON
      BY THE COMPANY

	 	 
	9.1 	
      The Subscriber acknowledges that the acknowledgements,
      representations and warranties contained herein are made by it with the
      intention that they may be relied upon by the Company and its legal
      counsel in determining the Subscriber's eligibility to purchase the Shares
      under applicable securities legislation, or (if applicable) the
      eligibility of others on whose behalf it is contracting hereunder to
      purchase the Shares under applicable securities legislation. The
      Subscriber further agrees that by accepting delivery of the certificates
      representing the Securities, it will be representing and warranting that
      the acknowledgements representations and warranties contained herein are
      true and correct as of the date hereof and the date of delivery and will
      continue in full force and effect notwithstanding any subsequent
      disposition by the Subscriber of all of the Securities.

	 	 
	10. 	
      REPRESENTATIONS AND WARRANTIES WILL BE RELIED UPON
      BY THE SUBSCRIBER

	 	 
	10.1 	
      The Company and Savicell acknowledge that the
      acknowledgements, representations and warranties contained herein are made
      by them with the intention that they may be relied upon by the Subscriber
      and its legal counsel in determining the Company's eligibility to
      subscribe the Shares under applicable securities legislation, or (if
      applicable) the eligibility of others on whose behalf it is contracting
      hereunder to purchase the Shares under applicable securities
      legislation.

	 	 
	11. 	
      RESALE RESTRICTIONS

	 	 
	11.1 	
      The Subscriber acknowledges that any resale of any of the
      Securities will be subject to resale restrictions contained in the
      securities legislation applicable to the Subscriber or proposed
      transferee. The Subscriber acknowledges that none of the Securities have
      been registered under the 1933 Act or the securities laws of any state of
      the United States. The Securities may not be offered or sold in the United
      States unless registered in accordance with federal securities laws and
      all applicable state securities laws or exemptions from such registration
      requirements are available.

	 	 
	11.2 	
      The Subscriber acknowledges that restrictions on the
      transfer, sale or other subsequent disposition of the Securities by the
      Subscriber may be imposed by securities laws in addition to any
      restrictions referred to above, and, in particular, the Subscriber
      acknowledges and agrees that none of the Securities may be offered or sold
      to a U.S. Person or for the account or benefit of a U.S. Person (other
      than a distributor) prior to the end of the Distribution Compliance
      Period.

- 13 - 

	12. 	
      LEGENDING OF SUBJECT SECURITIES

	 	 
	12.1 	
      The Subscriber hereby acknowledges that that upon the
      issuance thereof, and until such time as the same is no longer required
      under the applicable securities laws and regulations, the certificates
      representing any of the Securities will bear a legend in substantially the
      following form:

  
    
      
        
          “THESE SECURITIES WERE ISSUED IN AN OFFSHORE TRANSACTION TO
            PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE 1933 ACT)
            PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS
            AMENDED (THE “1933 ACT”). ACCORDINGLY, NONE OF THE SECURITIES TO WHICH THIS
            CERTIFICATE RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE
            SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD IN THE
            UNITED STATES OR, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS EXCEPT IN ACCORDANCE
            WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE
            REGISTRATION STATEMENT OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT
            SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY
            IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING
            TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE
            WITH THE 1933 ACT.” 

        

      

    

  

	12.2 	
      The Subscriber hereby acknowledges and agrees to the
      Company making a notation on its records or giving instructions to the
      registrar and transfer agent of the Company in order to implement the
      restrictions on transfer set forth and described in this Subscription
      Agreement.

	 	 
	13. 	
      COSTS

	 	 
	13.1 	
      The Subscriber acknowledges and agrees that all costs and
      expenses incurred by the Subscriber (including any fees and disbursements
      of any special counsel retained by the Subscriber) relating to the
      purchase of the Shares shall be borne by the Subscriber.

	 	 
	14. 	
      GOVERNING LAW

	 	 
	14.1 	
      This Subscription Agreement is governed by the laws of
      the State of Massachusetts. The Subscriber, in its personal or corporate
      capacity and, if applicable, on behalf of each beneficial purchaser for
      whom it is acting, irrevocably attorns to the exclusive jurisdiction of
      the Courts of the State of Massachusetts.

	 	 
	15. 	
      SURVIVAL

	 	 
	15.1 	
      This Subscription Agreement, including without limitation
      the representations, warranties and covenants contained herein, shall
      survive and continue in full force and effect and be binding upon the
      parties hereto notwithstanding the completion of the purchase of the
      Shares by the Subscriber pursuant hereto.

	 	 
	16. 	
      ASSIGNMENT

	 	 
	16.1 	
      This Subscription Agreement is not transferable or
      assignable.

- 14 - 

	17. 	
      SEVERABILITY

	 	 
	17.1 	
      The invalidity or unenforceability of any particular
      provision of this Subscription Agreement shall not affect or limit the
      validity or enforceability of the remaining provisions of this
      Subscription Agreement.

	 	 
	18. 	
      ENTIRE AGREEMENT

	 	 
	18.1 	
      Except as expressly provided in this Subscription
      Agreement and in the agreements, instruments and other documents
      contemplated or provided for herein, this Subscription Agreement contains
      the entire agreement between the parties with respect to the sale of the
      Shares and there are no other terms, conditions, representations or
      warranties, whether expressed, implied, oral or written, by statute or
      common law, by the Company or by anyone else.

	 	 
	19. 	
      NOTICES

	 	 
	19.1 	
      All notices and other communications hereunder shall be
      in writing and shall be deemed to have been duly given if mailed or
      transmitted by any standard form of telecommunication. Notices to the
      Subscriber shall be directed to the delivery address on Page 2 and notices
      to the Company shall be directed to it at the address stated on the first
      page of this Subscription Agreement.

	 	 
	20. 	
      COUNTERPARTS AND ELECTRONIC MEANS

	 	 
	20.1 	
      This Subscription Agreement may be executed in any number
      of counterparts, each of which, when so executed and delivered, shall
      constitute an original and all of which together shall constitute one
      instrument. Delivery of an executed copy of this Subscription Agreement by
      electronic facsimile transmission or other means of electronic
      communication capable of producing a printed copy will be deemed to be
      execution and delivery of this Subscription Agreement as of the date
      hereinafter set forth.Exhibit 4.61

 

EMPLOYMENT AGREEMENT

BETWEEN

CHINA SUNERGY CO., LTD.

AND

 

Mr. Tingxiu Lu

 

Dated: September 19, 2014

 

    	 

    	 

    

 

OFFSHORE EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT
(this “Agreement”). dated as of  September 19, 2014, is entered into by and between CHINA SUNERGY CO.,
LTD., a company organized and existing under the laws of the Cayman Islands (the “Company”), and Mr. Tingxiu
Lu (-Executive”), and shall become effective as of the date hereof (the “Effective Date”).

 

WHEREAS, the Company
desires to employ Executive and to enter into an agreement embodying the terms of such employment on and after the Effective Date
and considers it essential to its best interests and the best interests of its shareholders to foster the employment of Executive
by the Company during the term of this Agreement; and

 

WHEREAS, Executive
desires and is willing to enter into such employment with the Company and to enter into this Agreement; and

 

NOW, THEREFORE, in
consideration of the premises and mutual covenants herein and for other good and valuable consideration, the parties hereby agree
as follows:

 

1.Definitions.
For the purposes of this Agreement:

 

“Group”
means the Company and any company which is for the time being and from time to time, the holding company, parent, subsidiary or
Affiliate of the Company.

 

“Affiliate”
of a Person (the “Subject Person”) means any other Person directly or indirectly controlling, controlled by or
under common control with the Subject Person, where “control” means the possession, directly or indirectly, of
the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting
securities, by contract or otherwise, and includes (a) ownership directly or indirectly of 50% or more of the shares in issue or
other equity interests of such Person, (b) possession directly or indirectly of 50% or more of the voting power of such Person
or (c) the power directly or indirectly to appoint a majority of the members of the board of directors or similar governing body
of such Person, and the terms “controlling” and “controlled” have meanings correlative to the
foregoing.

 

“Person”,
for the purpose of this Agreement, means an individual, corporation, joint venture, enterprise, partnership, trust, unincorporated
association, limited liability company, government or any department or agency thereof, or any other entity.

 

2.Term of Employment.
Subject to the provisions of Section 8 of this Agreement, this Agreement shall be effective for a period commencing on the Effective
Date and ending on the day immediately preceding the fifth (5th) anniversary of the Effective Date (the “Initial
Term”); provided, however, that such term shall be automatically extended for successive twelve (12) month periods unless,
no later than sixty (60) days prior to the expiration of the Initial Term or any extension thereof, either party hereto shall provide
written notice to the other party hereto of its or his desire not to extend the term hereof (the Initial Term together with any
extension shall be referred to hereinafter as the “Employment Term”).

 

    	 

    	 

    

  

3.Position.

 

(a)Executive
shall serve as the Chief Executive Officer of the Company. In such position, Executive shall have such duties and authority
as shall be determined from time to time by the Board of Directors of the Company (the “Board”). Executive shall
report to the Board.

 

(b)During
the Employment Term, Executive will devote his business time and best efforts to the performance of his duties hereunder and will
not engage in any other business, profession or occupation for compensation or otherwise which would conflict with the rendition
of such services either directly or indirectly, without the prior written consent of the Board.

 

4.Base
Salary. During the Employment Term, the Company shall pay Executive a base salary (the “Base Salary”) at
the annual rate of $200,000, and other performance-related bonus at the annual rate of $200,000, payable in regular installments in accordance
with the Company’s usual payroll practices. The Board may from time to time review and increase the Base Salary in its sole
discretion. During the Employment Term, the Executive shall be eligible for any bonus program approved by the Board for the benefit
of the senior executives of the Company; provided however, that the foregoing shall not create any presumption that a bonus
will actually be granted by the Company to the Executive.

 

5.Employee
Benefits. During the Employment Term, Executive shall be provided with benefits on the same basis as benefits are generally
made available to other senior executives of the Company.

 

6.Vacation.
Executive shall be entitled to four (4) weeks annual paid vacation in accordance with the vacation accrual policy of the Company.

 

7.Business
Expenses. During the Employment Term, reasonable business expenses incurred by Executive in the performance of his duties hereunder
shall be reimbursed by the Company in accordance with Company policies.

 

8.Termination.
Notwithstanding any other provision of this Agreement:

 

(a)
For Cause by the Company. The Employment Term, and Executive’s employment hereunder, may be terminated at any time by the
Company for “Cause” (as defined below) upon delivery of a “Notice of Termination” (as defined in Section 8(e))
by the Company to Executive. For purposes of this Agreement, “Cause” shall mean, in each case, as reasonably
determined by the Board: (i) conviction of, or entry of a pleading of guilty or no contest by, Executive with respect to a felony
or any lesser crime of which fraud or dishonesty is a material element; (ii) Executive’s willful dishonesty towards the Company;
(iii) Executive’s willful and continued failure to perform substantially all of his duties with the Company, or a failure to follow
the lawful direction of the Board after the Board delivers a written demand for substantial performance and Executive neglects
to cure such a failure to the reasonable satisfaction of the Board within fifteen (15) days following receipt of such written
demand; (iv) Executive’s material, knowing and intentional failure to comply with applicable laws with respect to the execution
of the Company’s business operations or his material breach of this Agreement; (v) Executive’s theft, fraud, embezzlement, dishonesty
or similar conduct which has resulted or is likely to result in material damage to the Company or any of its affiliates or subsidiaries;
or (vi) Executive’s habitual intoxication or continued abuse of illegal drugs which materially interferes with Executive’s ability
to perform his assigned duties and responsibilities.

 

    	 

    	 

    

  

If Executive
is terminated for Cause pursuant to this Section 8(a), he shall be entitled to receive only his Base Salary and authorized benefits
through the date of termination and he shall have no further rights to any compensation (including any Base Salary or Bonus) or
any other benefits under this Agreement. All other benefits, if any, due to the Executive following Executive’s termination of
employment for Cause pursuant to this Section 8(a) shall be determined in accordance with the plans, policies and practices of
the Company; provided, however, that Executive shall not participate in any severance plan, policy or program of the Company.

 

(b)Disability
or Death. The Employment Term, and Executive’s employment hereunder, shall terminate immediately
upon his death or following delivery of a Notice of Termination by the Company to Executive if Executive becomes physically or
mentally incapacitated and is therefore unable for a period of ninety (90) consecutive days or one hundred twenty (120) days during
any consecutive six (6) month period to perform his duties with substantially the same level of quality as immediately prior to
such incapacity (such incapacity is hereinafter referred to as “Disability”). Upon termination of Executive’s
employment hereunder for either Disability or death, Executive or Executive’s estate (as the case may be) shall be entitled to
receive his Base Salary through the date of termination and any earned but unpaid Bonus for any calendar year preceding the year
in which the termination occurs. Executive or Executive’s estate (as the case may be) shall have no further rights to any compensation
(including any Base Salary or Bonus) or any other benefits under this Agreement. All other benefits, if any, due Executive following
Executive’s termination for Disability or death shall be determined in accordance with the plans, policies and practices of the
Company; provided, however, that Executive (or his estate, as the case may be) shall not participate in any severance plan, policy
or program of the Company.

 

(c)Without
Cause by the Company or for Good Reason by Executive. The Employment Term, and Executive’s
employment hereunder, may be terminated by the Company without Cause (other than by reason of Executive’s Disability) or by Executive
for “Good Reason” (as defined below) following the delivery of a Notice of Termination to the other party. If Executive’s
employment is terminated by the Company without Cause (other than by reason of Disability) or by Executive for Good Reason, Executive
shall receive, within thirty (30) days following termination, a lump sum payment of (i) any earned but unpaid Base Salary through
the date of termination and (ii) any earned but unpaid Bonus for any calendar year preceding the year in which the termination
occurs. In addition, subject to Executive’s compliance with Sections 9, 10 and 11, Executive shall continue to receive in bi-weekly
installments the Base Salary Executive would have otherwise received through the first (1st) anniversary of the date
of termination in the case of termination by the Company without Cause, or through the sixth (6th) month anniversary
of the date of termination in the case of termination by Executive for Good Reason; provided, however, that if necessary
to avoid additional or accelerated taxation pursuant to Section 409A of the Code, Executive will receive the first twelve (12)
installments of the foregoing payments on the six-month anniversary of the date of his termination in a lump sum payment and the
remainder of such payments, if any, shall thereafter be paid in bi-weekly installments through the first anniversary of the date
of termination. Executive shall have no further rights to any compensation

 

    	 

    	 

    

  

(including any Base Salary or
Bonus) or any other benefits under this Agreement. All other benefits, if any, due Executive following a termination pursuant to
this Section 8(c) shall be determined in accordance with the plans, policies and practices of the Company; provided, however, that
Executive shall not participate in any severance plan, policy or program of the Company. If Executive’s employment is terminated
pursuant to this Section 8(c), the continued payment of Base Salary shall be subject to Employee’s execution of a release in favor
of the Company, its affiliates and their respective officers, directors and employees in such form as may be required by the Company.

 

For purposes of this Agreement,
“Good Reason” means:

 

(i)          Any
failure by the Company to comply with any of the material provisions of this Agreement, other than an isolated, insubstantial and
inadvertent failure not occurring in bad faith;

 

(ii)         any
change in the duties or responsibilities (including reporting responsibilities) of Executive that is inconsistent in any material
and adverse respect with Executive’s position(s), duties or responsibilities with the. Company (including any material and adverse
diminution of such duties or responsibilities); provided, however, that Good Reason shall not be deemed to occur upon a
change in duties or responsibilities (other than reporting responsibilities) that is solely and directly a result of any event
set forth in Section 8(a), (b) or (d); or

 

(iii)        any
failure by the Company to comply with the provisions of Section 4 of this Agreement;

 

provided that a termination by
Executive with Good Reason shall be effective only if, within thirty (30) days following the delivery of a Notice of Termination
for Good Reason by Executive to the Company, the Company has failed to cure the circumstances giving rise to Good Reason.

 

(d)Termination
by Executive without Good Reason. The Employment Term, and Executive’s employment hereunder, may be terminated by Executive
without Good Reason following the delivery of a Notice of Termination to the Company. Upon a termination by Executive pursuant
to this Section 8(d), Executive shall be entitled to his Base Salary up to the date of such termination and he shall have no further
rights to any compensation (including any Base Salary or Bonus) or any other benefits under this Agreement. All other benefits,
if any, due Executive following termination pursuant to this Section 8(d) shall be determined in accordance with the plans, policies
and practices of the Company; provided, however, that Executive shall not participate in any severance plan, policy or program
of the Company.

 

    	 

    	 

    

 

(e)Notice
of Termination. Any purported termination of employment by the Company or Executive (other than on account of the death of
Executive) shall be communicated by a written Notice of Termination to Executive or the Company, respectively, delivered in accordance
with Section 14(j) hereof. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which
shall indicate the specific termination provision in this Agreement relied upon, the date of termination, and shall set forth in
reasonable detail the facts and circumstances claimed to provide a basis for termination of employment under the provision so indicated.
The date of termination of Executive’s employment shall be the date so stated in the Notice of Termination and shall be no less
than thirty (30) days following the delivery of a Notice of Termination; except that in the case of a termination by the
Company for Cause in accordance with the terms of Section 8(a) hereof, in which case the date of termination of Executive’s employment
may be, at the sole discretion of the Company, the same date as the delivery of the Notice of Termination.

 

9. Non-Competition/Non-Solicitation.

 

(a) Executive
acknowledges and recognizes the highly competitive nature of the “Business” (as defined below) of the Company and its
subsidiaries and affiliates and accordingly agrees as follows:

 

(i)          (A)
The term “Business” means the manufacturing, whether directly by the Company or through its various subsidiaries
or Affiliates (including without limitation NJPV), of photovoltaic cells and such other related business activities as the Company
may engage in from time to time; (B) Executive has intimate and valuable knowledge of the Business, as well as technical, financial,
customer, supplier and other confidential information related to the Business, which, if exploited by Executive in contravention
of the terms of this Agreement, would seriously, adversely and irreparably affect the ability of the Company to continue the Business;
(C) the agreements and covenants contained in this Agreement, as they relate to the Business and otherwise, have been determined
by the Company to be essential to protect the Business and goodwill of the Company; (D) for purposes of this Section 9, the Company
shall be construed to include the Company and its subsidiaries and affiliates; and (E) Executive has the means to support himself
and his dependents other than by engaging in the Business, and the provisions of this Agreement will not impair such ability in
any manner whatsoever.

 

(ii)         During
the Employment Term and until the third anniversary of the date Executive ceases to be employed by the Company (the “Restricted
Period”), unless otherwise indicated in the disclosure letter, Executive will not directly or indirectly (A) engage in
the Business for Executive’s own account in China, (B) enter the employ of, or render any services to, any Person engaged in the
Business in the PRC, (C) acquire a financial interest in, or otherwise become actively involved with, any person engaged in the
Business in the PRC, directly or indirectly (and whether or not for compensation), as an individual, partner, shareholder, officer,
director, principal, agent, trustee or consultant, or (D) interfere with business relationships (whether formed before or after
the Effective Date) between the Company and customers or suppliers of, or consultants to, the Company.

 

(iii)        During
the Employment Term, Executive agrees not to appropriate, or fail to promptly notify and turn over to the Company any corporate
opportunity relating to or arising in connection with the Business of the Group, or engage in any activity that is detrimental
to the business of the Group or that limits the ability of the Group to fully exploit such corporate opportunities or prevents
the benefits of such corporate opportunities from accruing to the Group. For the avoidance of doubt, Executive may, by himself
or through any entity controlled by him, engage in activities relating to solar power stations business or, only when, after
using best efforts, any entity within the Group fails to obtain the relevant governmental approvals, in activities in connection
with the Business of the Group.

 

    	 

    	 

    

  

(iv)        Notwithstanding
anything to the contrary in this Agreement, Executive may, directly or indirectly, own, solely through passive ownership as a portfolio
investment (with no director designation rights or other special governance rights), securities of any person engaged in the Business
which are publicly traded on a national or regional stock exchange or on the over-the-counter market if Executive (A) is not a
controlling person of, or a member of a group which controls, such person and (B) does not, directly or indirectly, own 1% or more
of any class of securities of such person.

 

(v)         During
the Restricted Period, Executive will not, directly or indirectly, solicit or encourage to cease to work with the Company, or directly
or indirectly hire, any person who is an employee of or consultant then under contract with the Company or who was an employee
of or consultant then under contract with the Company within the one year preceding such activity without the Company’s written
consent.

 

(b) It is expressly
understood and agreed that although Executive and the Company consider the restrictions contained in this Section 9 to be reasonable,
if a judicial determination is made by a court of competent jurisdiction that the time or territory or any other restriction contained
in this Agreement is an unenforceable restriction against Executive, the provisions of this Agreement shall not be rendered void
but shall be deemed amended to apply as to such maximum time and territory and to such maximum extent as such court may judicially
determine or indicate to be enforceable. Alternatively, if any court of competent jurisdiction finds that any restriction contained
in this Agreement is unenforceable, and such restriction cannot be amended so as to make it enforceable, such finding shall not
affect the enforceability of any of the other restrictions contained herein.

 

10.
Nondisparagement. Executive agrees (whether during or after Executive’s employment with the Company) not to issue,
circulate, publish or utter any false or disparaging statements, remarks or rumors about the Company or its affiliates or the
officers, directors, managers or shareholders of the Company or its affiliates unless giving truthful testimony under
subpoena.

 

11.
Confidentiality. Executive shall not, without the prior written consent of the Company, use, divulge, disclose or make
accessible to any other person, firm, partnership, corporation or other entity, any “Confidential Information” (as
defined below) except while employed by the Company, in furtherance of the business of and for the benefit of the Company or
its affiliates; provided that Executive may disclose such information when required to do so by a court of competent
jurisdiction, by any governmental agency having supervisory authority over the business of the Company and/or its affiliates,
as the case may be, or by any administrative body or legislative body (including a committee thereof) with jurisdiction to
order Executive to divulge, disclose or make accessible such information; provided, further, that in the event that Executive
is ordered by a court or other government agency to disclose any Confidential Information or Personal Information, Executive
shall (i) promptly notify the Company of such order, (ii) at the written request of the Company, diligently contest such
order at the sole expense of the Company as expenses occur, and (iii) at the written request of the Company, seek to obtain,
at the sole expense of the Company, such confidential treatment as may be available under applicable laws for any information
disclosed under such order. For purposes of this Section 11, “Confidential Information” shall mean
non-public information concerning the financial data, strategic business plans, product development (or other
proprietary product data), customer lists, marketing plans and other non-public, proprietary and confidential information
relating to the business of the Company or its subsidiaries, affiliates or customers, that, in any case, is not otherwise
available to the public (other than by Executive’s breach of the terms hereof). Upon termination of Executive’s employment
with the Company and its affiliates, Executive shall return all Company property, including, without limitation, files,
records, disks and any media containing Confidential Information, including all copies thereto.

 

    	 

    	 

    

  

12. Assignment of Inventions.

 

(a)Exhibit
A hereto lists all inventions, original works of authorship, developments, improvements, and trade secrets which were made
by the Executive prior to his employment with the Company (collectively referred to as “Prior Inventions”), which
belong to the Executive, which relate to the Company’s Business, products or research and development, and which are not assigned
to the Company hereunder; or, if no such list is attached, the Executive represents that there are no such Prior Inventions.

 

(b)If
in the course of his employment with the Company, the Executive incorporates into a product, process or machine of the Company
and/or any other member of the Group a Prior Invention owned by him or in which he have an interest, the Company and/or any member
of the Group is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make,
have made, modify, use and sell such Prior Invention as part of or in connection with such product, process or machine.

 

(c)The
Executive shall promptly make full written disclosure to the Company, will hold in trust for the sole right and benefit of the
Company, and hereby assign, free or charge, to the Company, or its designee, all the right, title, and interest he may have in
and to any and all inventions, original works of authorship, developments, concepts, improvements, designs, discoveries, ideas,
trademarks or trade secrets, processes, copyright works, know-how, Confidential Information, any other work’s information or matter
which gives rise or may give rise to any intellectual property of whatsoever nature, whether or not patentable or registrable
under any law of any country, which he may solely or jointly conceive or develop or reduce to practice, or cause to be conceived
or developed or reduced to practice, during his employment with the Company (collectively referred to as “Inventions”),
except as provided in Section 12(j) below.

 

(d)The Executive
acknowledges that the Company, or its designee, has the absolute title, right or interest in and to any and all original inventions
or works of authorship which are made by him, as an employee, (solely or jointly with others) within the scope of and during the
period of the employment with the Company and which inventions and works are the “service invention-creation” and “works
made for hire” as defined under applicable law. If any one or more of the aforementioned Inventions can be protected by copyright
and are not considered to be “service invention-creation” or “works made for hire” as defined under applicable
law, such items shall be deemed to be assigned and transferred completely and exclusively to the Company, or its designee, by virtue
of the execution of this Agreement by the Executive.

 

    	 

    	 

    

  

(e)The Executive
acknowledges that the decision whether or not to commercialize or market any invention developed by him solely or jointly with
others is within the Company’ sole discretion and for the sole benefit of the Company and/or any other member of the Group, and
that no royalty will be due to the Executive as a result of the Company’s efforts (or the efforts of any member of the Group) to
commercialize or market any such Invention.

 

(f)The Executive
shall keep and maintain adequate and current written records of all Inventions made by him (solely or jointly with others) during
the term of his employment with the Company. The records will be in the form of notes, sketches, drawings, and any other format
that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times.

 

(g)The Executive
shall assist the Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s (or its designee’s)
rights m the Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating thereto in
any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the
execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary
ih order to apply for and obtain such rights and in order to assign and convey to its successors, assigns, and nominees the sole
and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual
property rights relating thereto, and to do all other things reasonably requested by the Company, or its designee, (both during
and after the term of this Agreement) in order to vest more fully in the Company, or its designee, all ownership rights in the
Inventions.

 

(h)If the Company
is unable because of the Executive’s mental or physical incapacity or for any other reason to secure his signature to apply for
or to pursue any application for any United States, PRC or foreign patents or copyright registrations covering Inventions or original
works of authorship assigned to the Company as set forth above, the Executive hereby irrevocably designates and appoints the Company
and its duly authorized officers and agents as his agent and attorney in fact, to act for and in his behalf and stead to execute
and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent
or copyright registrations thereon with the same legal force and effect as if executed by the Executive.

 

(i)  With
respect to Inventions that are not considered as “service invention-creation” or “works made for
hire” under applicable law, to the extent that any application, registration or other governmental processes may be
required in order to protect the Company’s, or its designee’s ownership of any Inventions, the Executive hereby grants the
Company, or its designee, an irrevocable power of attorney to execute all documents and do all acts in his name as the
Company, or its designee, may deem necessary or advisable to effect such processes and agrees to diligently and faithfully
assist the Company, or its designee, in effecting such processes.

 

(j) Any
assignment of any Inventions under this Agreement includes all rights of paternity, integrity, disclosure and withdrawal and any
other rights that may be known as or referred to as “moral rights- (collectively “Moral Rights”).
To the extent such Moral Rights cannot be assigned under applicable law and to the extent the following is allowed by the laws
in the various countries where such Moral Rights exist, the Executive hereby waives such Moral Rights and consent to any action
of the Company, or its designee, that would violate such Moral Rights in the absence of such consent. The Executive hereby covenants
to confirm any such waivers and consents from time to time as requested by the Company, or its designee.

 

    	 

    	 

    

  

(k)In
respect of any inventions which are not Inventions but which relate to the business of the Company or Group, the Company or any
member of the Group shall have a pre-emptive right to acquire for itself or its nominee all or any part (at the Company’s option)
of the Executive’s rights therein within three (3) months of their disclosure by the Executive to the Company under Section 12(c)
above on such terms as shall be agreed by the Company and Executive. In the event that the Company or any member of the Group decides
not to acquire such inventions, the Executive hereby grants to the Company, a perpetual, worldwide, irrevocable, royalty-free,
fully paid-up, exclusive license to use for any and all purposes and in any manner any such other inventions that are within the
scope of the actual and anticipated business of the Company or the Group.

 

13. Enforcement
of Restrictive Covenants. Executive acknowledges and agrees that the Company’s remedies at law for a breach or threatened
breach of any of the provisions of Sections 9, 10, 11 or 12 herein would be inadequate and, in recognition of this fact,
Executive agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company,
without posting any bond, shall be entitled to obtain equitable relief in the form of specific performance, temporary
restraining order, temporary or permanent injunction or any other equitable remedy which may then be available. In addition,
upon a violation by Executive of Section 9, 10, 11 or 12, as determined in good faith by the Board, all payments remaining
due to Executive pursuant to Section 8(c), if applicable, shall immediately cease.

 

14. Miscellaneous.

 

(a)
Acceptance. Executive hereby represents that his performance and execution of this Agreement does not and will not constitute
a breach of any agreement or arrangement to which he is a party or is otherwise bound, including, without limitation, any noncompetition
or employment agreement.

 

(b)GOVERNING
LAW; CONSENT TO JURISDICTION. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
NEW YORK OF THE UNITED STATES OF AMERICA APPLICABLE TO AGREEMENTS MADE AND TO BE WHOLLY PERFORMED WITHIN THAT STATE, WITHOUT REGARD
TO THE CONFLICT OF LAWS PROVISIONS OF ANY JURISDICTION WHICH WOULD CAUSE THE APPLICATION OF ANY LAW OTHER THAN THAT OF THE STATE
OF NEW YORK. ANY ACTION TO ENFORCE THIS AGREEMENT AND/OR THE EXHIBITS HERETO (OTHER THAN AN ACTION WHICH MUST BE BROUGHT BY ARBITRATION
PURSUANT TO SECTION 14(d)) MUST BE BROUGHT IN, AND THE PARTIES HEREBY CONSENT TO THE JURISDICTION OF, A COURT SITUATED IN NEW YORK
COUNTY, NEW YORK. EACH PARTY HEREBY WAIVES THE RIGHTS TO CLAIM THAT ANY SUCH COURT IS AN INCONVENIENT FORUM FOR THE RESOLUTION
OF ANY SUCH ACTION.

 

    	 

    	 

    

 

(c)JURY
TRIAL WAIVER. THE PARTIES EXPRESSLY AND KNOWINGLY WAIVE ANY RIGHT TO A JURY TRIAL IN THE EVENT ANY ACTION ARISING UNDER OR
IN CONNECTION WITH THIS AGREEMENT OR EXECUTIVE’S EMPLOYMENT WITH THE COMPANY IS LITIGATED OR HEARD IN ANY COURT.

 

(d)Arbitration;
Legal Fees. Except to the extent contemplated by Section 13, any dispute, controversy or other claim arising out of or relating
to (i) this Agreement, or (ii) Executive’s employment with the Company shall be resolved by binding confidential arbitration before
a single arbitrator, to be held in New York, New York in accordance with the Commercial Arbitration Rules of the American Arbitration
Association. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. Each party
shall be responsible for its own expenses relating to the conduct of the arbitration or litigation (including reasonable attorneys’
fees and expenses) and shall share the fees of the American Arbitration Association and the arbitrator, if applicable, equally.

 

(e)Entire
Agreement/Effectiveness of this Agreement. This Agreement constitutes the entire agreement between the parties as of the Effective
Date and supersedes all previous agreements and understandings between the parties with respect to the subject matter thereof.
Executive hereby acknowledges and agrees that. the Prior Employment Agreement shall terminate as of immediately prior to the Effective
Date and Executive shall have no further rights thereunder and the Company and its affiliates shall have no further obligations
thereunder.

 

(f)Amendments.
There are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties with respect to the
subject matter herein other than those expressly set forth herein. This Agreement may not be altered, modified, or amended except
by written instrument signed by the parties hereto. Sections 9, 10, 11, 12 and 13 survive the termination of this Agreement and
the termination of Executive’s employment with the Company, except as otherwise specifically stated therein.

 

(g)
No Waiver. The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not be
considered a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence to that
term or any other term of this Agreement.

 

(h)Severability.
In the event that any one or more of the provisions of this Agreement shall be or become invalid, illegal or unenforceable in any
respect, each such provision shall be processed with whatever deletion or modification is necessary so that the provision is otherwise
legal, valid and enforceable and gives effect to the commercial intention of the parties. To the extent it is not possible to delete
or modify the provision, in whole or in part, then such provision or part of it shall, to the extent that it is illegal, invalid
or unenforceable, be deemed not to form part of this Agreement and the validity, legality and enforceability of the remaining provisions
of this Agreement shall, subject to any deletion or modification made hereunder, not be affected.

 

    	 

    	 

    

 

(i) Assignment. Executive shall not have the right to assign his interest in this Agreement, any rights under this Agreement
or any duties imposed under this Agreement. This Agreement may be assigned by the Company to any successor in interest to
substantially all of the business operations of the Company. Such assignment shall become effective when the Company notifies
Executive of such assignment or at such later date as may be specified in such notice. Upon such assignment, the rights and
obligations of the Company hereunder shall become the rights and obligations of such successor company.

 

(j)Notice.
For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and
shall be deemed to have been duly given if delivered personally, if delivered by overnight courier service, if sent by facsimile
transmission or if mailed by registered mail, return receipt requested, postage prepaid, addressed to the respective addresses
or sent via facsimile to the respective facsimile numbers, as the case may be, as set forth below, or to such other address as
either party may have ‘furnished to the other in writing in accordance herewith, except that notice of change of address shall
be effective only upon receipt; provided, however, that (i) notices sent by personal delivery or overnight courier shall be deemed
given when delivered; (ii) notices sent by facsimile transmission shall be deemed given upon the sender’s receipt of confirmation
of complete transmission, and (iii) notices sent by United States registered mail shall be deemed given seven (7) days after the
date of deposit in the United States mail.

 

If to Executive, to:

 

123 Focheng West Road

Jiangning Economic & Technical
Development Zone

Nanjing, PRC 211100

Facsimile: +86 (25) 5276-6882

Attention: Lu Tingxiu

If to the Company, to:

123 Focheng West Road

Jiangning Economic & Technical
Development Zone

Nanjing, PRC 211100

Facsimile: +86 (25) 5276-6882

Attention: Lu Tingxiu

 

(k) Withholding
Taxes. The Company may withhold from any amounts payable under this Agreement such Federal, state, local and foreign taxes
as may be required to be withheld pursuant to any applicable law or regulation.

 

(1) Continuation
of Employment. Unless the parties otherwise agree in writing, continuation of Executive’s employment with the Company beyond
the expiration of the Employment Term shall be deemed an employment “at will” and shall not be deemed to extend any
of the provisions of this Agreement, and Executive’s employment may thereafter be terminated at will by Executive or the Company.

 

(m) Counterparts.
This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument.

 

[THE REMAINDER OF THIS PAGE IS
INTENTIONALLY LEFT BLANK]

 

    	 

    	 

    

 

IN WITNESS
WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

 

	 	EXECUTIVE
	 	 
	 	/s/ Tingxiu
    Lu
	 	 
	 	CHINA SUNERGY CO., LTD.
	 	 
	 	By:	/s/ Tingxiu Lu

	 	Name: Tingxiu Lu

	 	Title: Authorized Representative

 

    	 

    	 

    

 

EXHIBIT A

 

Prior Inventions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]